Abnormalities in the expression of cytokines and their receptors in patients with myelodysplastic syndromes.

被引:0
|
作者
FontenayRoupie, M
Dreyfus, F
机构
来源
PATHOLOGIE BIOLOGIE | 1997年 / 45卷 / 07期
关键词
cytokines; receptors;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Abnormalities of the expression of cytokines and their receptors seen in myelodysplastic syndromes (MDS) are reviewed. Autocrine and paracrine secretion of growth factors, most notably GM-CSF and IL-6, has been identified as a factor in clone expansion in young pediatric patients with chronic myelomonocytic leukemia. Mutations affecting cFMS, the receptor for M-CSF, have also been demonstrated. The other reported abnormalities have been found in too small a number of cases to explain the cell growth and differentiation disorders seen during the course of MDS. It remains possible, however, that a more detailed study of signal transduction pathways might detect functional abnormalities explaining the contrast between the small number of reported cases with abnormalities at the cytokine and cytokine receptor sites and the cell growth and differentiation disorders that are prominent in MDS.
引用
收藏
页码:569 / 572
页数:4
相关论文
共 50 条
  • [31] Progress in myelodysplastic syndromes. Introduction
    Kelaidi, Charikleia
    Fenaux, Pierre
    HEMATOLOGIE, 2006, 12 : 2 - 2
  • [32] Iron overload and myelodysplastic syndromes.
    Rose, C
    Cambier, N
    Mahieu, M
    Ernst, O
    Fenaux, P
    TRANSFUSION CLINIQUE ET BIOLOGIQUE, 2001, 8 (05) : 422 - 432
  • [33] Microvascular density in bone marrow of patients with myelodysplastic syndromes.
    Machhi, J
    Bunyi-Teopengco, E
    Chang, C
    Shidham, VB
    Wang, G
    Kampalath, B
    MODERN PATHOLOGY, 2001, 14 (01) : 171A - 171A
  • [34] Endogenous serum thrombopoietin levels in patients with myelodysplastic syndromes.
    Zwierzina, H
    RollingerHolzinger, I
    Herold, M
    Nuessler, V
    Meng, YG
    BLOOD, 1995, 86 (10) : 1330 - 1330
  • [35] Systemic diseases in myelodysplastic syndromes.
    Hebbar, M
    HebbarSavean, K
    Fenaux, P
    REVUE DE MEDECINE INTERNE, 1995, 16 (12): : 897 - 904
  • [36] Cyclosporine a without or with thalidomide for the treatment of patients with Myelodysplastic syndromes.
    Xiao, Zhijian
    Xu, Zefeng
    Wang, Jianxiang
    Hao, Yushu
    BLOOD, 2007, 110 (11) : 222B - 222B
  • [37] Economic burden of transfusion dependence in patients with myelodysplastic syndromes.
    Frytak, JR
    Henk, H
    Nelson, M
    Decastro, C
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 544S - 544S
  • [38] Microvascular density in bone marrow of patients with myelodysplastic syndromes.
    Machhi, J
    Bunyi-Teopengco, E
    Chang, C
    Shidham, VB
    Wang, G
    Kampalath, B
    LABORATORY INVESTIGATION, 2001, 81 (01) : 171A - 171A
  • [39] Relationship between immunological abnormalities and paroxysmal nocturnal hemoglobinuria clones in myelodysplastic syndromes.
    Okada, M
    Okamoto, T
    Takatsuka, H
    Wada, H
    Fujimori, Y
    Kakihsita, E
    BLOOD, 2000, 96 (11) : 149A - 149A
  • [40] Evidence of immunologic abnormalities in myelodysplastic syndromes. A matched case-control study
    Poullin, P
    Saddier, P
    NicolinoBrunet, C
    Consiatori, M
    Georges, F
    Sampol, J
    Gabriel, B
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 257 - 257